Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 2/20 | 0.49 |
| ▸ | PPARG | P37231 | 3/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 8/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.37 |
| ▸ | RPS6KA5 | O75582 | 3/20 | 0.37 |
| ▸ | AKT1 | P31749 | 3/20 | 0.37 |
| ▸ | GSK3B | P49841 | 3/20 | 0.37 |
| ▸ | NEK4 | P51957 | 3/20 | 0.37 |
| ▸ | PRKCD | Q05655 | 3/20 | 0.37 |
| ▸ | PRKG2 | Q13237 | 3/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.37 |
| ▸ | PRKG1 | Q13976 | 3/20 | 0.37 |
| ▸ | PKN2 | Q16513 | 3/20 | 0.37 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.37 |
| ▸ | CDK2 | P24941 | 3/20 | 0.37 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.37 |
| ▸ | PRKCG | P05129 | 2/20 | 0.37 |
| ▸ | CDK1 | P06493 | 2/20 | 0.37 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6978654 | 0.79 | F10 (0.48) | F10MAPK1ROCK2AKT1ROCK1 | |
| SCHEMBL6978650 | 0.78 | F10 (0.47) | F10MAPK1CDK2PAK4 | |
| SCHEMBL6981248 | 0.78 | F10 (0.54) | F10PPARGMAPK1ROCK2RPS6KA5 | |
| SCHEMBL6983223 | 0.78 | F10 (0.49) | F10MAPK1ROCK2ROCK1 | |
| SCHEMBL7133910 | 0.76 | F10 (0.50) | F10PPARGMAPK1ROCK2RPS6KA5 | |
| SCHEMBL6982560 | 0.75 | F10 (0.52) | F10PPARGMAPK1ROCK2ROCK1 | |
| SCHEMBL6982556 | 0.75 | F10 (0.52) | F10PPARGMAPK1ROCK2ROCK1 | |
| SCHEMBL7952274 | 0.75 | F10 (0.51) | F10PPARGMAPK1ROCK2RPS6KA5 | |
| SCHEMBL6978051 | 0.74 | F10 (0.49) | F10PPARGMAPK1ROCK2RPS6KA5 | |
| SCHEMBL6978044 | 0.74 | F10 (0.49) | F10PPARGMAPK1ROCK2RPS6KA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1012166-B1 | 1-AMINO-7-ISOQUINOLINE DERIVATIVES AS SERINE PROTEASE INHIBITORS | TULARIK LTD (GB) | 2003-10-29 | — | — | EP | disclosed |
| US-6420438-B1 | FOR THERAPY OF THROMBOTIC DISEASE, ASTHMA, EMPHYSEMA, CIRRHOSIS, ARTHRITIS, CARCINOMA, MELANOMA, RESTENOIS, ATHEROMA, TRAUMA, SHOCK AND REPERFUSION INJURY | TULARIK LIMITED (GB) | 2002-07-16 | — | — | US | disclosed |
| US-20020040144-A1 | 1-amino-7-isoquinoline derivatives as serine protease inhibitors | TULARIK LIMITED (GB) | 2002-04-04 | — | — | US | disclosed |
| US-6262069-B1 | 1-amino-7-isoquinoline derivatives as serine protease inhibitors | PROTHERICS MOLECULAR DESIGN LIMITED (GB) | 2001-07-17 | — | — | US | disclosed |
| EP-1012166-A1 | 1-AMINO-7-ISOQUINOLINE DERIVATIVES AS SERINE PROTEASE INHIBITORS | Protherics Molecular Design Limited (GB) | 2000-06-28 | — | — | EP | disclosed |
| WO-1999011657-A1 | 1-AMINO-7-ISOQUINOLINE DERIVATIVES AS SERINE PROTEASE INHIBITORS | PROTEUS MOLECULAR DESIGN LTD. (GB) | 1999-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040144-A1 | 1-amino-7-isoquinoline derivatives as serine protease inhibitors | CTRL, HPN, CTSL | F10 1211/4885PPARG 4764/4885MAPK1 2278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.